Cerus Corporation reported its financial results for the second quarter of 2025, revealing a total revenue of $60.1 million, a 19% increase from $50.5 million in the same period last year. This growth was driven by a 16% rise in product revenue, which reached $52.4 million, primarily due to increased sales of disposable platelet kits in Europe. Government contract revenue also saw a significant increase of 41%, totaling $7.7 million, attributed to heightened activity under its agreements with the Biomedical Advanced Research and Development Authority (BARDA).
In terms of profitability, Cerus recorded a net loss of $5.7 million for the quarter, slightly down from a loss of $5.8 million in the prior year. The company’s operating expenses rose to $40.1 million, up from $33.9 million, largely due to increased research and development costs associated with its new LED-based illuminator and higher compensation expenses. The gross margin on product sales remained stable at 55% for the quarter, with a slight increase to 57% for the first half of 2025 compared to 55% in the same period of 2024.
Operationally, Cerus reported a total of 191.7 million shares of common stock outstanding as of July 17, 2025. The company continues to focus on expanding its market presence, particularly in the U.S. and Europe, where it has received regulatory approvals for its INTERCEPT Blood System for platelets and plasma. The company is also working on the development of its red blood cell system, which is currently undergoing clinical trials. However, the timeline for regulatory approval remains uncertain, as the company must address questions raised by regulatory bodies regarding its product data.
Looking ahead, Cerus anticipates continued growth in product revenue driven by increased market acceptance of the INTERCEPT Blood System. The company expects government contract revenue to rise as multiple contracts become active and activities ramp up. However, it also faces challenges, including potential delays in regulatory approvals for its red blood cell system and the need for additional funding to support ongoing development activities. The company’s cash and cash equivalents stood at $16.0 million as of June 30, 2025, down from $20.3 million at the end of 2024, indicating a need for careful management of its financial resources as it navigates these challenges.
About CERUS CORP
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.